top of page

Publications

science-template-dna-molecules-background-vector-id1036121728.jpg
image.png

Ascending single-dose study of the safety, pharmacokinetics, and pharmacodynamics of CSTI-500, a novel monoamine triple reuptake inhibitor, first-in-human

Phase 1 SAD results demonstrated that CSTI-500, a potent triple monoamine reuptake inhibitor (TRI), achieves substantial striatal SERT occupancy and moderate DAT occupancy in healthy subjects. Combined with a favorable safety, tolerability, and pharmacokinetic profile, these findings strongly support the continued clinical development of CSTI-500.

​

Pubmed link here

bottom of page